The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.
Int J Mol Sci. 2022 Mar 31;23(7):3871. doi: 10.3390/ijms23073871.
Int J Mol Sci. 2022.
PMID: 35409229
Free PMC article.
Review.